UBI reminds me of CXL as a company that can leverage its technology across various sectors: in this case, biosensors used in winemaking, human & veterinary health, agriculture & environment.

Xprecia Stride coagulation testing product well established  (with next gen expected in 2022), while Sentia wine analyzer (launched March 21) already purchased by 7% of Australian wine producers, with distribution deals in most major wine producing countries.

45% workforce turnover since appointment of new CEO (John Sharman, 10 years as MVP CEO) in June 20, indicating a change of culture: "We have moved away from defining ourselves as a Research and Development (R&D) company with long lead times and expensive research programs".

Interesting update with a string of new products planned for 2022 and beyond. Complements the recent Sequoia report posted by laoshi